Latest / Community Health Media
Dr. Seth Wander & Dr. Erica Mayer - SERENA-6 and Camizestrant in Breast Cancer
Can early intervention change the course of metastatic HR+ breast cancer?
In this expert discussion, Dr. Seth Wander and Dr. Erica Mayer break down the practice-changing SERENA-6 trial and the emerging role of camizestrant in ESR1-mutated metastatic breast cancer.
From ctDNA monitoring and early resistance detection, to quality-of-life improvements and precision endocrine therapy—they explore how oral SERDs may redefine treatment sequencing in HR-positive, HER2-negative disease.
Topics include:
• SERENA-6 trial design and results
• ESR1 mutations and endocrine resistance
• ctDNA-guided…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.